Endocrine emergencies are potentially life-threatening clinical problems and are
compounded by a lack of recognition leading to delays in therapy. Every endocrinologist
is aware of patients attending their out-patient clinic, with tales of suboptimal care
in a non-endocrine clinical environment because of a failure to understand their chronic
condition and its possible complications. This is particularly relevant in adrenal
insufficiency and has led to potentially avoidable excess morbidity and mortality.To address this issue, the Clinical Committee of the Society for Endocrinology have
launched a new initiative to introduce succinct and straightforward clinical guidance
documents for use by the non-endocrinologist within an emergency setting. Five Emergency
Guidance documents have been developed, often in conjunction with more comprehensive
European, American or National guidelines. For the first time, all five are published
together in this issue of Endocrine Connections.Each guidance document covers the most common endocrine-themed medical emergencies:Adrenal insufficiency (1): this is often
under-recognised and, in particular, there is a lack of understanding of
‘sick day rules’ amongst non-endocrine health professionals. This
document clearly outlines key points in the recognition and management of a new
presentation of adrenal insufficiency as well as clarifying how to alter
glucocorticoid therapy in the event of intercurrent illness of medical procedures.
The lead author of this guideline is Professor Weibke Arlt who was also an author
on the Endocrine Society Clinical Practice Guideline and the diagnosis and
treatment of primary adrenal insufficiency published in 2016 (2).Severe symptomatic hyponatraemia (3): this
has been principally authored by Professor Stephen Ball who was also an author of
the Clinical Practice guideline on hyponatraemia developed by the European Society
for Endocrinology in 2014 (4). The
particular strength of this guidance is that it emphasises the importance of
assessing the severity of acute hyponatraemia and treating accordingly in the
first instance. Evaluation of volume status and confirming the exact cause of
hyponatraemia, whilst important, are often done poorly by non-specialist
clinicians and delay the appropriate treatment of this common and potentially
life-threatening condition.Acute hypocalcaemia (5) and hypercalcaemia
(6): disorders of calcium regulation
are the second most common electrolyte disorder requiring endocrine input. In
these documents, Professor Jeremy Turner, Dr Jennifer Walsh and colleagues provide
a concise summary of the key causes of hypocalcaemia and hypercalcaemia and their
immediate management based upon biochemical severity and underlying cause: in the
case of hypercalcaemia, the first step is rehydration with normal saline, and
intravenous zoledronic acid is now the bisphosphonate of choice.Pituitary apoplexy (7): in this condition,
recognition and prompt treatment with intravenous hydrocortisone may be
life-saving and prevent long-term visual complications. In this guidance, Dr
Stephanie Baldeweg and colleagues emphasise that this condition must be considered
in patients with acute severe headache, visual defects and/or impairment of
consciousness. Authors of this Emergency Guidance were also authors on the Society
for Endocrinology’s UK Guidelines for the management of pituitary apoplexy,
published in 2011 and reviewed with no necessary changes in 2014 (8).Each guidance document has been principally written by authors with extensive experience
and expertise in the relevant condition with consideration of the most up to date
evidence available and has been peer-reviewed by the Society for Endocrinology Clinical
Committee.The Society wishes to distribute these important documents as widely as possible to a
non-endocrine audience, most notably Emergency Departments and acute general medical and
surgical wards. Publication of all documents in Endocrine Connections
and subsequent availability on the Society for Endocrinology website will allow
endocrinologists to provide a single point of reference to non-specialist colleagues to
guide the management of these extremely common and important conditions.
Declaration of interest
The author declares that there is no conflict of interest that could be perceived as
prejudicing the impartiality of this editorial.
Funding
This work did not receive any specific grant from any funding agency in the public,
commercial, or not-for-profit sector.
Authors: Senthil Rajasekaran; Mark Vanderpump; Stephanie Baldeweg; Will Drake; Narendra Reddy; Marian Lanyon; Andrew Markey; Gordon Plant; Michael Powell; Saurabh Sinha; John Wass Journal: Clin Endocrinol (Oxf) Date: 2011-01 Impact factor: 3.478
Authors: Goce Spasovski; Raymond Vanholder; Bruno Allolio; Djillali Annane; Steve Ball; Daniel Bichet; Guy Decaux; Wiebke Fenske; Ewout J Hoorn; Carole Ichai; Michael Joannidis; Alain Soupart; Robert Zietse; Maria Haller; Sabine van der Veer; Wim Van Biesen; Evi Nagler Journal: Eur J Endocrinol Date: 2014-02-25 Impact factor: 6.664
Authors: Stephanie E Baldeweg; Mark Vanderpump; Will Drake; Narendra Reddy; Andrew Markey; Gordon T Plant; Michael Powell; Saurabh Sinha; John Wass Journal: Endocr Connect Date: 2016-09 Impact factor: 3.335
Authors: Stefan R Bornstein; Bruno Allolio; Wiebke Arlt; Andreas Barthel; Andrew Don-Wauchope; Gary D Hammer; Eystein S Husebye; Deborah P Merke; M Hassan Murad; Constantine A Stratakis; David J Torpy Journal: J Clin Endocrinol Metab Date: 2016-01-13 Impact factor: 5.958